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Previewsunderlying diseases, and medical treat-
ments all are features of patient history
that influence human microbial composi-
tion and could determine individual re-
sponses to NAS consumption. We do
not know whether NAS select against
certain microbes by inhibiting their func-
tion, allowing their unaffected competi-
tors to flourish, or whether they are
direct stimulants of other organisms, or
both. The mode of selection remains to
be determined, but the problem is trac-
table. Also unclear is whether metabolic
effects relate to differences in food
and liquid intake between experimental
groups. Future studies should carefully
control intakes to minimize potential
cofounder effects.
Biological variation similarly defines
patient susceptibility to other microbe-
mediated treatments, such as drug
metabolism (Maurice et al., 2013) and
dietary responses (Salonen et al.,
2014). These studies all highlight the
need to establish how microbial varia-tion influences host responses to diet,
therapies, and disease. The develop-
ment and implementation of personal-
ized treatments for complex diseases
could likely involve manipulation of the
microbiota.
In the interim, the findings of Suez and
colleagues have more immediate conse-
quences: that dietary sugar alternatives
meant to stave off the risk of obesity and
diabetes may actually increase disease
risk due to microbial alterations (Suez
et al., 2014). Other dietary additives may
provoke similar microbial changes and
deserve further investigation. This is yet
another indication that we are not alone
and that microbial disturbances can lead
to unexpected physiological effects.REFERENCES
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A substantive literature has accumulated implicating sphingolipids, in particular ceramides, as mediators
of insulin resistance in metabolic syndrome. Thanks to recent technical advances in mouse genetics and lip-
idomics, two independent laboratories identify the same sphingolipid, C16:0-ceramide, as principal mediator
of obesity-related insulin resistance (Turpin et al., 2014; Raichur et al., 2014).The term ‘‘metabolic syndrome’’ defines
a constellation of distinct clinical entities
that present together in aging populations
of wealthy and newly developed nations.
Insulin resistance, obesity, hyperlipid-
emia, and hypertension represent core
abnormalities of metabolic syndrome.
This syndrome accelerates progression
of major diseases such as atherosclerotic
vascular disease and type 2 diabetes,
leading to increased morbidity and mor-
tality. Refinement of criteria to improveour understanding of progression of these
comorbid conditions is an active area of
ongoing investigation (Eckel et al., 2010).
Much evidence supports altered sphin-
golipid metabolism and, more specif-
ically, enhanced ceramide generation as
integral to progression of type 2 diabetes
and insulin resistance, contributing to
metabolic syndrome (Chavez and Sum-
mers, 2012). In addition to ceramide,
glycosphingolipid metabolism may be
deregulated in type 2 diabetes (Hla andDannenberg, 2012). Thus, molecular
description of specific sphingolipid spe-
cies-mediating disease pathophysiology
is critical. As estimates of the number of
bioactive sphingolipid mediators range
from 4,000 to 60,000 (Merrill, 2011), this
is indeed a daunting challenge. Now,
two Cell Metabolism articles conclude
that a specific ceramide species, C16:0-
ceramide, mediates the key pathophysi-
ology of insulin resistance (Turpin et al.,
2014; Raichur et al., 2014).November 4, 2014 ª2014 Elsevier Inc. 703
Figure 1. Impact of High-Fat Diet-Induced C16:0-Ceramide on Metabolic Dysregulation
Sphingolipid synthesis begins with condensation of palmitoyl-CoAwith serine forming 3-ketosphinganine,
which is reduced to dihydrosphingosine (a.k.a. sphinganine) and thereafter acylated to dihydroceramide.
Further reduction of the sphingoid base sphinganine backbone by formation of a trans-double bond yields
ceramide, a central molecule in sphingolipid metabolism. Transfer of a phosphocholine headgroup from
phosphatidylcholine to ceramide yields sphingomyelin, the most abundant mammalian sphingolipid,
concentrated in the external plasma membrane, while glycosylation in Golgi begins the formation of a
plethora of glycosphingolipids with complex carbohydrate headgroups. Alternately, ceramide deacylation
by ceramidase frees up sphingosine for compartmentalized phosphorylation yielding sphingosine 1-phos-
phate. In the context of insulin resistance, high-fat diet selectively upregulates expression of CerS6, the
C16:0-ceramide synthetic enzyme, and concomitantly provides increased amounts of the CerS6 sub-
strate palmitate, enhancing C16:0-ceramide production. C16:0-ceramide induces insulin resistance by
antagonizing insulin receptor (IR)-stimulated PI3K/Akt signaling, which attenuates glucose metabolism.
In addition, Akt normally stimulates lipid metabolism by SREBP-dependent mechanisms, which would
presumably be inhibited, although not directly investigated in the current manuscripts. C16:0-ceramide
also appears to directly inhibit mitochondrial electron transport, by an as-yet-unknown mechanism,
thereby indirectly suppressing b-oxidation. Inhibition of b-oxidation reduces fatty acid disposal, promoting
accumulation of excessive TG in lipid droplets.
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PreviewsSphingolipids serve two distinct and
interrelated purposes in eukaryotes:
they act as building blocks of biologic
membranes and as bioactive lipids.
Although sphingosine 1-phosphate was
originally considered a classic second
messenger, it is now recognized as an
extracellularly acting lipid mediator
signaling via G protein-coupled receptors
to regulate multiple organ systems (Hla
and Dannenberg, 2012). In contrast, ce-
ramides, often generated after stress,
mediate complex intracellular functions
in a topographically restricted manner.
For instance, plasma membrane stress
in some cells (i.e., endothelium, hepato-
cytes, oocytes) releases acid sphingo-
myelinase from secretory vesicles,
generating cell-surface ceramide within704 Cell Metabolism 20, November 4, 2014 ªseconds, whereas unrepaired DNA dam-
age in numerous cells stimulates pro-
longed de novo ceramide synthesis via
ceramide synthase in mitochondrial
membranes, which, either as an intact
molecule or after processed degrada-
tion to hexadecenal, triggers mitochon-
drial outer membrane permeabilization
commitment to apoptosis (Chipuk et al.,
2012).
Two complementary papers pub-
lished in Cell Metabolism independently
conclude that C16:0-ceramide mediates
the pathophysiology of insulin resistance
(Turpin et al., 2014; Raichur et al., 2014)
(Figure 1). These studies were made
possible by recent cloning of the six
mammalian ceramide synthases (CerS1–
6), which acylate sphinganine to distinct2014 Elsevier Inc.dihydroceramides or in some instances
free sphingosine to ceramides (salvage
pathway) (Chavez and Summers, 2012);
development of mass spectrometry-
based lipidomic analysis of long-chain
ceramide (C16:0–C20:0) and very-long-
chain ceramide (C22:0–C24:1) species
(Merrill, 2011); and a growing awareness
that different ceramide species manifest
specific biologic properties. A developing
consensus is that while C16:0-ceramide
is proapoptotic, the C24-ceramide series
confers antiapoptotic and proliferative
functions (Park et al., 2014). These differ-
ences may reflect the impact of different
ceramide species on biophysical proper-
ties of membranes, as C16:0-ceramide
is the only ceramide species so far shown
to be capable of inducing generation of
ceramide-rich platforms, large (1–5 mM)
nonbilayer structures in mammalian
membranes into which select proteins
insert and oligomerize for transmembrane
signal transmission (Stancevic and Koles-
nick, 2010).
Both teams use mouse genetics to
address insulin resistance mechanisms.
Turpin et al. (2014) show that wild-
type mice on a high-fat diet (HFD) mani-
fest increased long-chain ceramides
and selectively increased expression
of CerS6, the enzyme responsible for
mammalian C16:0-ceramide synthesis.
CerS6 knockout mice, which accommo-
date loss of C16:0-ceramide by upregu-
lating C24-ceramides, among others,
display minor abnormalities at baseline,
yet are protected from HFD-induced
obesity and glucose intolerance. Protec-
tion from diet-induced obesity (DIO) is
manifest as reduction in body weight,
adiposity, adipocyte size, serum leptin,
macrophage infiltration, and proinflam-
matory gene expression in white adi-
pose tissue (WAT). Concomitantly, CerS6
knockouts display decreased circulating
insulin, and increased glucose tolerance,
insulin sensitivity, and activation of insulin
effector signaling kinases: Akt and its
target GSK3b in liver.
Turpin et al. (2014) went the extra
distance, making tissue-specific Cers6
knockouts inmacrophagesandbrownad-
ipose tissue (BAT). Whereas CerS6 dele-
tion in macrophages had little impact on
the panoply of abnormalities observed in
DIO, 50% loss of CerS6 in BAT reduced
DIO and improved energy expenditure.
Adipocytes isolated from CerS6 knockout
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Previewsmice displayed increased mitochondrial
b-oxidative capacity, while glycolysis was
unaltered. Liver-specific CerS6 knockouts
displayed only subtle protection from
HFD-induced weight gain, yet significantly
improved glucose intolerance. Further-
more, isolated hepatocytes from this strain
displayed protection from palmitate-
induced attenuation of insulin-stimulated
Akt activation. Altogether, these studies
support a critical role for CerS6-derived
C16:0-ceramide in obesity-related meta-
bolic syndrome.
Raichur et al. (2014) used heterozygous
CerS2 knockout mice, which manifest
reduction of C24 series ceramides and
compensatory upregulation of C16:0-cer-
amide. Such compensatory reregulation
of ceramide species to maintain overall
ceramide levels is a developing theme.
On normal chow, CerS2+/ mice were
indistinguishable from wild-type mice;
however, on HFD CerS2+/ mice dis-
played increased liver weight, triglycer-
ides, macrophage infiltration, circulating
liver enzymes, and plasma cholesterol,
indicating liver damage. These mice also
displayed slightly impaired glucose toler-
ance, high fasting and fed insulin levels,
increased circulating insulin upon glucose
tolerance testing, decreased insulin
sensitivity during insulin tolerance testing,
decreased ambulatory activity, and
increased fat to lean mass, accompanied
by a small reduction in insulin-induced Akt
phosphorylation. Altogether, this resem-
bles a phenotype opposite to the CerS6
knockout. Critically, myriocin, a specific
serine-palmitoyl transferase inhibitor, re-
duces ceramide species and abrogates
CerS2+/ insulin resistance, indicating it
is not loss of the C24 series that mediates
insulin resistance, but rather C16:0-cer-
amide upregulation.
Detailed analysis of genes involved in
triglyceride synthesis ruled out transcrip-
tional regulation as the mechanism of
triglyceride accumulation in CerS2+/
mice, nor was there reduced lipoproteinsynthesis. To address mechanism, Rai-
chur et al. (2014) resorted to primary
hepatocyte culture. Indeed CerS2+/ he-
patocytes display the insulin-resistant
phenotype ex vivo. Further, they accumu-
late medium-chain acyl-carnitines impli-
cated in cardiovascular pathology (Shah
et al., 2012) and exhibit markedly dimin-
ished rates of fatty acid oxidation, basal
respiration, ATP turnover, and maximal
and spare respiratory activity. Analysis
of electron transport chain complexes
revealed reduced Complex II and IV ac-
tivity. Further, hepatocytes isolated from
myriocin-treated wild-type mice showed
increased Complex IV activity. Consis-
tent with C16:0-ceramide as mediator of
metabolic syndrome, adenoviral CerS6
overexpression in wild-type C57BL6/J
hepatocytes reduced Complex II activity,
leading to increased triglyceride accumu-
lation and reduced insulin-stimulated Akt
phosphorylation. In contrast to studies
using CerS6 knockouts, CerS2+/ mice
do not display altered body weight or en-
ergy expenditure, consistent with C16:0-
ceramide metabolic effects as primarily
exerted in liver.
Novel insights developed from these
studies are likely relevant to human meta-
bolic syndrome. Raichur et al. (2014)
report that genome-wide analyses reveal
a human CerS2 polymorphism, a single
amino acid substitution at CerS2 position
115, that associates strongly with insulin
resistance markers. Delineation of this
polymorphism vis-a`-vis metabolic syn-
drome is underway. Even more specif-
ically, Turpin et al. (2014) report data
from 439 human subjects across a broad
spectrum of body masses. While visceral
and subcutaneous WAT express CerS1,
CerS2, CerS4, CerS5, and CerS6, only
CerS6 expression positively correlated
with obesity and insulin resistance.
Further, in a small cohort of lean versus
obese human subjects, long-chain cer-
amide, in particular C16:0-ceramide, was
increased in obese visceral WAT, whileCell Metabolism 20,most very-long-chain ceramides were
not, strengthening association of meta-
bolic syndrome with C16:0-ceramide.
We have only recently entered the era of
sphingolipid therapeutics. Fingolimod/Gi-
lenya, a sphingosine 1-phosphate recep-
tor functional antagonist, was approved
in 2010 as an orally available, first-line
therapy for relapsing-remitting multi-
ple sclerosis. In August 2014, the FDA
approved the glucosylceramide synthase
inhibitor Cerdelga (Eliglustat) for treat-
ment of Gaucher’s disease, the first highly
effective non-enzyme-replacement ther-
apy for an inherited sphingolipidosis.
Numerous other small-molecule sphingo-
lipid therapeutics are in development and
clinical trials. We believe this newfound
therapeutic landscape supports the pos-
sibility of specific CerS6/C16:0-ceramide
inhibition asapotential treatment of insulin
resistance and metabolic syndrome.REFERENCES
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